Stay updated on Comparing Fenebrutinib vs Teriflunomide in RMS Clinical Trial
Sign up to get notified when there's something new on the Comparing Fenebrutinib vs Teriflunomide in RMS Clinical Trial page.

Latest updates to the Comparing Fenebrutinib vs Teriflunomide in RMS Clinical Trial page
- Check7 days agoChange DetectedThe record describes a Phase 3 study comparing fenebrutinib with teriflunomide for relapsing multiple sclerosis, including eligibility criteria, study outcomes, and participating locations.SummaryDifference95%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide notice announces that NIH content may use “Super Intelligence” alongside “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov 403 error page footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe 403 error block and its HTML boilerplate (including the 403 text and Home link) were removed from the page.SummaryDifference0.5%

Stay in the know with updates to Comparing Fenebrutinib vs Teriflunomide in RMS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Fenebrutinib vs Teriflunomide in RMS Clinical Trial page.